1	4	_	_	_	_	_	_	_	_
2	.	_	_	_	_	_	_	_	_


1	Discussion	_	_	_	_	_	_	_	_


1	The	_	_	_	_	_	_	_	_
2	present	_	_	_	_	_	_	_	_
3	study	_	_	_	_	_	_	_	_
4	confirms	_	_	_	_	_	_	_	_
5	that	_	_	_	_	_	_	_	_
6	a	_	_	_	_	_	_	_	_
7	remarkable	_	_	_	_	_	_	_	_
8	number	_	_	_	_	_	_	_	_
9	of	_	_	_	_	_	_	_	_
10	patients	_	_	_	_	_	_	_	_
11	with	_	_	_	_	_	_	_	_
12	ACC	_	_	_	_	_	_	_	_
13	who	_	_	_	_	_	_	_	_
14	are	_	_	_	_	_	_	_	_
15	operated	_	_	_	_	_	_	_	_
16	on	_	_	_	_	_	_	_	_
17	with	_	_	_	_	_	_	_	_
18	radical	_	_	_	_	_	_	_	_
19	intent	_	_	_	_	_	_	_	_
20	are	_	_	_	_	_	_	_	_
21	destined	_	_	_	_	_	_	_	_
22	to	_	_	_	_	_	_	_	_
23	relapse	_	_	_	_	_	_	_	_
24	.	_	_	_	_	_	_	_	_


1	ACC	_	_	_	_	_	_	_	_
2	recurrence	_	_	_	_	_	_	_	_
3	portends	_	_	_	_	_	_	_	_
4	a	_	_	_	_	_	_	_	_
5	worse	_	_	_	_	_	_	_	_
6	prognosis	_	_	_	_	_	_	_	_
7	and	_	_	_	_	_	_	_	_
8	has	_	_	_	_	_	_	_	_
9	a	_	_	_	_	_	_	_	_
10	huge	_	_	_	_	_	_	_	_
11	impact	_	_	_	_	_	_	_	_
12	on	_	_	_	_	_	_	_	_
13	quality	_	_	_	_	_	_	_	_
14	of	_	_	_	_	_	_	_	_
15	life	_	_	_	_	_	_	_	_
16	;	_	_	_	_	_	_	_	_
17	therefore	_	_	_	_	_	_	_	_
18	,	_	_	_	_	_	_	_	_
19	investigators	_	_	_	_	_	_	_	_
20	have	_	_	_	_	_	_	_	_
21	considered	_	_	_	_	_	_	_	_
22	the	_	_	_	_	_	_	_	_
23	use	_	_	_	_	_	_	_	_
24	of	_	_	_	_	_	_	_	_
25	adjuvant	_	_	_	_	_	_	_	_
26	mitotane	_	_	_	_	_	_	_	_
27	therapy	_	_	_	_	_	_	_	_
28	following	_	_	_	_	_	_	_	_
29	surgical	_	_	_	_	_	_	_	_
30	operation	_	_	_	_	_	_	_	_
31	.	_	_	_	_	_	_	_	_


1	However	_	_	_	_	_	_	_	_
2	,	_	_	_	_	_	_	_	_
3	a	_	_	_	_	_	_	_	_
4	limited	_	_	_	_	_	_	_	_
5	number	_	_	_	_	_	_	_	_
6	of	_	_	_	_	_	_	_	_
7	often	_	_	_	_	_	_	_	_
8	small-sized	_	_	_	_	_	_	_	_
9	studies	_	_	_	_	_	_	_	_
10	reporting	_	_	_	_	_	_	_	_
11	the	_	_	_	_	_	_	_	_
12	outcome	_	_	_	_	_	_	_	_
13	of	_	_	_	_	_	_	_	_
14	adjuvant	_	_	_	_	_	_	_	_
15	mitotane	_	_	_	_	_	_	_	_
16	is	_	_	_	_	_	_	_	_
17	available	_	_	_	_	_	_	_	_
18	.	_	_	_	_	_	_	_	_


1	In	_	_	_	_	_	_	_	_
2	the	_	_	_	_	_	_	_	_
3	present	_	_	_	_	_	_	_	_
4	study	_	_	_	_	_	_	_	_
5	,	_	_	_	_	_	_	_	_
6	we	_	_	_	_	_	_	_	_
7	explored	_	_	_	_	_	_	_	_
8	the	_	_	_	_	_	_	_	_
9	relationship	_	_	_	_	_	_	_	_
10	between	_	_	_	_	_	_	_	_
11	target	_	_	_	_	_	_	_	_
12	mitotane	_	_	_	_	_	_	_	_
13	concentrations	_	_	_	_	_	_	_	_
14	and	_	_	_	_	_	_	_	_
15	patient	_	_	_	_	_	_	_	_
16	outcome	_	_	_	_	_	_	_	_
17	using	_	_	_	_	_	_	_	_
18	the	_	_	_	_	_	_	_	_
19	TTR	_	_	_	_	_	_	_	_
20	,	_	_	_	_	_	_	_	_
21	analogous	_	_	_	_	_	_	_	_
22	to	_	_	_	_	_	_	_	_
23	warfarin	_	_	_	_	_	_	_	_
24	treatment	_	_	_	_	_	_	_	_
25	.	_	_	_	_	_	_	_	_


1	Some	_	_	_	_	_	_	_	_
2	previous	_	_	_	_	_	_	_	_
3	studies	_	_	_	_	_	_	_	_
4	used	_	_	_	_	_	_	_	_
5	the	_	_	_	_	_	_	_	_
6	peak	_	_	_	_	_	_	_	_
7	mitotane	_	_	_	_	_	_	_	_
8	level	_	_	_	_	_	_	_	_
9	,	_	_	_	_	_	_	_	_
10	which	_	_	_	_	_	_	_	_
11	cannot	_	_	_	_	_	_	_	_
12	give	_	_	_	_	_	_	_	_
13	an	_	_	_	_	_	_	_	_
14	adequate	_	_	_	_	_	_	_	_
15	representation	_	_	_	_	_	_	_	_
16	since	_	_	_	_	_	_	_	_
17	it	_	_	_	_	_	_	_	_
18	is	_	_	_	_	_	_	_	_
19	a	_	_	_	_	_	_	_	_
20	measurement	_	_	_	_	_	_	_	_
21	at	_	_	_	_	_	_	_	_
22	a	_	_	_	_	_	_	_	_
23	single	_	_	_	_	_	_	_	_
24	point	_	_	_	_	_	_	_	_
25	in	_	_	_	_	_	_	_	_
26	time	_	_	_	_	_	_	_	_
27	.	_	_	_	_	_	_	_	_


1	In	_	_	_	_	_	_	_	_
2	other	_	_	_	_	_	_	_	_
3	studies	_	_	_	_	_	_	_	_
4	,	_	_	_	_	_	_	_	_
5	the	_	_	_	_	_	_	_	_
6	percentage	_	_	_	_	_	_	_	_
7	of	_	_	_	_	_	_	_	_
8	mitotane	_	_	_	_	_	_	_	_
9	measurements	_	_	_	_	_	_	_	_
10	in	_	_	_	_	_	_	_	_
11	a	_	_	_	_	_	_	_	_
12	range	_	_	_	_	_	_	_	_
13	was	_	_	_	_	_	_	_	_
14	used	_	_	_	_	_	_	_	_
15	,	_	_	_	_	_	_	_	_
16	but	_	_	_	_	_	_	_	_
17	this	_	_	_	_	_	_	_	_
18	method	_	_	_	_	_	_	_	_
19	has	_	_	_	_	_	_	_	_
20	the	_	_	_	_	_	_	_	_
21	caveat	_	_	_	_	_	_	_	_
22	of	_	_	_	_	_	_	_	_
23	being	_	_	_	_	_	_	_	_
24	strongly	_	_	_	_	_	_	_	_
25	dependent	_	_	_	_	_	_	_	_
26	on	_	_	_	_	_	_	_	_
27	the	_	_	_	_	_	_	_	_
28	number	_	_	_	_	_	_	_	_
29	of	_	_	_	_	_	_	_	_
30	available	_	_	_	_	_	_	_	_
31	measurements	_	_	_	_	_	_	_	_
32	.	_	_	_	_	_	_	_	_


1	This	_	_	_	_	_	_	_	_
2	may	_	_	_	_	_	_	_	_
3	introduce	_	_	_	_	_	_	_	_
4	a	_	_	_	_	_	_	_	_
5	bias	_	_	_	_	_	_	_	_
6	when	_	_	_	_	_	_	_	_
7	comparing	_	_	_	_	_	_	_	_
8	patients	_	_	_	_	_	_	_	_
9	with	_	_	_	_	_	_	_	_
10	different	_	_	_	_	_	_	_	_
11	durations	_	_	_	_	_	_	_	_
12	of	_	_	_	_	_	_	_	_
13	follow-ups	_	_	_	_	_	_	_	_
14	,	_	_	_	_	_	_	_	_
15	which	_	_	_	_	_	_	_	_
16	may	_	_	_	_	_	_	_	_
17	be	_	_	_	_	_	_	_	_
18	quite	_	_	_	_	_	_	_	_
19	prolonged	_	_	_	_	_	_	_	_
20	in	_	_	_	_	_	_	_	_
21	the	_	_	_	_	_	_	_	_
22	case	_	_	_	_	_	_	_	_
23	of	_	_	_	_	_	_	_	_
24	adjuvant	_	_	_	_	_	_	_	_
25	therapy	_	_	_	_	_	_	_	_
26	.	_	_	_	_	_	_	_	_


1	Moreover	_	_	_	_	_	_	_	_
2	,	_	_	_	_	_	_	_	_
3	there	_	_	_	_	_	_	_	_
4	is	_	_	_	_	_	_	_	_
5	no	_	_	_	_	_	_	_	_
6	evidence	_	_	_	_	_	_	_	_
7	to	_	_	_	_	_	_	_	_
8	define	_	_	_	_	_	_	_	_
9	what	_	_	_	_	_	_	_	_
10	percentage	_	_	_	_	_	_	_	_
11	level	_	_	_	_	_	_	_	_
12	identifies	_	_	_	_	_	_	_	_
13	a	_	_	_	_	_	_	_	_
14	good	_	_	_	_	_	_	_	_
15	exposure	_	_	_	_	_	_	_	_
16	to	_	_	_	_	_	_	_	_
17	mitotane	_	_	_	_	_	_	_	_
18	.	_	_	_	_	_	_	_	_


1	These	_	_	_	_	_	_	_	_
2	methodological	_	_	_	_	_	_	_	_
3	issues	_	_	_	_	_	_	_	_
4	may	_	_	_	_	_	_	_	_
5	have	_	_	_	_	_	_	_	_
6	contributed	_	_	_	_	_	_	_	_
7	to	_	_	_	_	_	_	_	_
8	the	_	_	_	_	_	_	_	_
9	discrepancy	_	_	_	_	_	_	_	_
10	in	_	_	_	_	_	_	_	_
11	the	_	_	_	_	_	_	_	_
12	literature	_	_	_	_	_	_	_	_
13	concerning	_	_	_	_	_	_	_	_
14	adjuvant	_	_	_	_	_	_	_	_
15	treatment	_	_	_	_	_	_	_	_
16	.	_	_	_	_	_	_	_	_


1	In	_	_	_	_	_	_	_	_
2	the	_	_	_	_	_	_	_	_
3	present	_	_	_	_	_	_	_	_
4	study	_	_	_	_	_	_	_	_
5	,	_	_	_	_	_	_	_	_
6	we	_	_	_	_	_	_	_	_
7	calculated	_	_	_	_	_	_	_	_
8	the	_	_	_	_	_	_	_	_
9	TTR	_	_	_	_	_	_	_	_
10	,	_	_	_	_	_	_	_	_
11	which	_	_	_	_	_	_	_	_
12	in	_	_	_	_	_	_	_	_
13	our	_	_	_	_	_	_	_	_
14	opinion	_	_	_	_	_	_	_	_
15	gives	_	_	_	_	_	_	_	_
16	a	_	_	_	_	_	_	_	_
17	more	_	_	_	_	_	_	_	_
18	adequate	_	_	_	_	_	_	_	_
19	representation	_	_	_	_	_	_	_	_
20	of	_	_	_	_	_	_	_	_
21	chronic	_	_	_	_	_	_	_	_
22	exposure	_	_	_	_	_	_	_	_
23	to	_	_	_	_	_	_	_	_
24	mitotane	_	_	_	_	_	_	_	_
25	,	_	_	_	_	_	_	_	_
26	and	_	_	_	_	_	_	_	_
27	analyzed	_	_	_	_	_	_	_	_
28	the	_	_	_	_	_	_	_	_
29	results	_	_	_	_	_	_	_	_
30	in	_	_	_	_	_	_	_	_
31	a	_	_	_	_	_	_	_	_
32	multivariate	_	_	_	_	_	_	_	_
33	analysis	_	_	_	_	_	_	_	_
34	without	_	_	_	_	_	_	_	_
35	predefining	_	_	_	_	_	_	_	_
36	arbitrary	_	_	_	_	_	_	_	_
37	cutoff	_	_	_	_	_	_	_	_
38	values	_	_	_	_	_	_	_	_
39	.	_	_	_	_	_	_	_	_


1	We	_	_	_	_	_	_	_	_
2	found	_	_	_	_	_	_	_	_
3	an	_	_	_	_	_	_	_	_
4	inverse	_	_	_	_	_	_	_	_
5	relationship	_	_	_	_	_	_	_	_
6	between	_	_	_	_	_	_	_	_
7	the	_	_	_	_	_	_	_	_
8	TTR	_	_	_	_	_	_	_	_
9	and	_	_	_	_	_	_	_	_
10	risk	_	_	_	_	_	_	_	_
11	of	_	_	_	_	_	_	_	_
12	ACC	_	_	_	_	_	_	_	_
13	recurrence	_	_	_	_	_	_	_	_
14	,	_	_	_	_	_	_	_	_
15	implying	_	_	_	_	_	_	_	_
16	that	_	_	_	_	_	_	_	_
17	the	_	_	_	_	_	_	_	_
18	greater	_	_	_	_	_	_	_	_
19	the	_	_	_	_	_	_	_	_
20	TTR	_	_	_	_	_	_	_	_
21	,	_	_	_	_	_	_	_	_
22	the	_	_	_	_	_	_	_	_
23	lower	_	_	_	_	_	_	_	_
24	the	_	_	_	_	_	_	_	_
25	risk	_	_	_	_	_	_	_	_
26	.	_	_	_	_	_	_	_	_


1	This	_	_	_	_	_	_	_	_
2	finding	_	_	_	_	_	_	_	_
3	supports	_	_	_	_	_	_	_	_
4	the	_	_	_	_	_	_	_	_
5	clinical	_	_	_	_	_	_	_	_
6	value	_	_	_	_	_	_	_	_
7	of	_	_	_	_	_	_	_	_
8	mitotane	_	_	_	_	_	_	_	_
9	monitoring	_	_	_	_	_	_	_	_
10	and	_	_	_	_	_	_	_	_
11	the	_	_	_	_	_	_	_	_
12	concept	_	_	_	_	_	_	_	_
13	of	_	_	_	_	_	_	_	_
14	target	_	_	_	_	_	_	_	_
15	doses	_	_	_	_	_	_	_	_
16	in	_	_	_	_	_	_	_	_
17	the	_	_	_	_	_	_	_	_
18	adjuvant	_	_	_	_	_	_	_	_
19	setting	_	_	_	_	_	_	_	_
20	.	_	_	_	_	_	_	_	_


1	Although	_	_	_	_	_	_	_	_
2	it	_	_	_	_	_	_	_	_
3	is	_	_	_	_	_	_	_	_
4	plausible	_	_	_	_	_	_	_	_
5	that	_	_	_	_	_	_	_	_
6	lower	_	_	_	_	_	_	_	_
7	mitotane	_	_	_	_	_	_	_	_
8	concentrations	_	_	_	_	_	_	_	_
9	may	_	_	_	_	_	_	_	_
10	be	_	_	_	_	_	_	_	_
11	effective	_	_	_	_	_	_	_	_
12	in	_	_	_	_	_	_	_	_
13	an	_	_	_	_	_	_	_	_
14	adjuvant	_	_	_	_	_	_	_	_
15	treatment	_	_	_	_	_	_	_	_
16	,	_	_	_	_	_	_	_	_
17	we	_	_	_	_	_	_	_	_
18	analyzed	_	_	_	_	_	_	_	_
19	only	_	_	_	_	_	_	_	_
20	the	_	_	_	_	_	_	_	_
21	level	_	_	_	_	_	_	_	_
22	of	_	_	_	_	_	_	_	_
23	14	_	_	_	_	_	_	_	_
24	mg/L	_	_	_	_	_	_	_	_
25	,	_	_	_	_	_	_	_	_
26	because	_	_	_	_	_	_	_	_
27	this	_	_	_	_	_	_	_	_
28	was	_	_	_	_	_	_	_	_
29	the	_	_	_	_	_	_	_	_
30	target	_	_	_	_	_	_	_	_
31	in	_	_	_	_	_	_	_	_
32	our	_	_	_	_	_	_	_	_
33	practice	_	_	_	_	_	_	_	_
34	.	_	_	_	_	_	_	_	_


1	The	_	_	_	_	_	_	_	_
2	time	_	_	_	_	_	_	_	_
3	needed	_	_	_	_	_	_	_	_
4	to	_	_	_	_	_	_	_	_
5	achieve	_	_	_	_	_	_	_	_
6	target	_	_	_	_	_	_	_	_
7	mitotane	_	_	_	_	_	_	_	_
8	concentrations	_	_	_	_	_	_	_	_
9	also	_	_	_	_	_	_	_	_
10	has	_	_	_	_	_	_	_	_
11	an	_	_	_	_	_	_	_	_
12	impact	_	_	_	_	_	_	_	_
13	on	_	_	_	_	_	_	_	_
14	the	_	_	_	_	_	_	_	_
15	risk	_	_	_	_	_	_	_	_
16	of	_	_	_	_	_	_	_	_
17	ACC	_	_	_	_	_	_	_	_
18	recurrence	_	_	_	_	_	_	_	_
19	:	_	_	_	_	_	_	_	_
20	a	_	_	_	_	_	_	_	_
21	longer	_	_	_	_	_	_	_	_
22	time	_	_	_	_	_	_	_	_
23	was	_	_	_	_	_	_	_	_
24	associated	_	_	_	_	_	_	_	_
25	with	_	_	_	_	_	_	_	_
26	higher	_	_	_	_	_	_	_	_
27	risk	_	_	_	_	_	_	_	_
28	.	_	_	_	_	_	_	_	_


1	This	_	_	_	_	_	_	_	_
2	is	_	_	_	_	_	_	_	_
3	consistent	_	_	_	_	_	_	_	_
4	with	_	_	_	_	_	_	_	_
5	the	_	_	_	_	_	_	_	_
6	concept	_	_	_	_	_	_	_	_
7	that	_	_	_	_	_	_	_	_
8	mitotane	_	_	_	_	_	_	_	_
9	is	_	_	_	_	_	_	_	_
10	a	_	_	_	_	_	_	_	_
11	slow-acting	_	_	_	_	_	_	_	_
12	drug	_	_	_	_	_	_	_	_
13	in	_	_	_	_	_	_	_	_
14	relation	_	_	_	_	_	_	_	_
15	to	_	_	_	_	_	_	_	_
16	the	_	_	_	_	_	_	_	_
17	achievement	_	_	_	_	_	_	_	_
18	of	_	_	_	_	_	_	_	_
19	significant	_	_	_	_	_	_	_	_
20	plasma	_	_	_	_	_	_	_	_
21	levels	_	_	_	_	_	_	_	_
22	.	_	_	_	_	_	_	_	_


1	Due	_	_	_	_	_	_	_	_
2	to	_	_	_	_	_	_	_	_
3	the	_	_	_	_	_	_	_	_
4	very	_	_	_	_	_	_	_	_
5	cautious	_	_	_	_	_	_	_	_
6	dose	_	_	_	_	_	_	_	_
7	titration	_	_	_	_	_	_	_	_
8	in	_	_	_	_	_	_	_	_
9	the	_	_	_	_	_	_	_	_
10	starting	_	_	_	_	_	_	_	_
11	phase	_	_	_	_	_	_	_	_
12	of	_	_	_	_	_	_	_	_
13	treatment	_	_	_	_	_	_	_	_
14	employed	_	_	_	_	_	_	_	_
15	in	_	_	_	_	_	_	_	_
16	many	_	_	_	_	_	_	_	_
17	centers	_	_	_	_	_	_	_	_
18	,	_	_	_	_	_	_	_	_
19	the	_	_	_	_	_	_	_	_
20	time	_	_	_	_	_	_	_	_
21	needed	_	_	_	_	_	_	_	_
22	to	_	_	_	_	_	_	_	_
23	get	_	_	_	_	_	_	_	_
24	into	_	_	_	_	_	_	_	_
25	the	_	_	_	_	_	_	_	_
26	target	_	_	_	_	_	_	_	_
27	range	_	_	_	_	_	_	_	_
28	was	_	_	_	_	_	_	_	_
29	exceedingly	_	_	_	_	_	_	_	_
30	long	_	_	_	_	_	_	_	_
31	.	_	_	_	_	_	_	_	_


1	We	_	_	_	_	_	_	_	_
2	identified	_	_	_	_	_	_	_	_
3	a	_	_	_	_	_	_	_	_
4	time	_	_	_	_	_	_	_	_
5	point	_	_	_	_	_	_	_	_
6	at	_	_	_	_	_	_	_	_
7	17	_	_	_	_	_	_	_	_
8	months	_	_	_	_	_	_	_	_
9	to	_	_	_	_	_	_	_	_
10	achieve	_	_	_	_	_	_	_	_
11	target	_	_	_	_	_	_	_	_
12	concentrations	_	_	_	_	_	_	_	_
13	,	_	_	_	_	_	_	_	_
14	which	_	_	_	_	_	_	_	_
15	significantly	_	_	_	_	_	_	_	_
16	differentiates	_	_	_	_	_	_	_	_
17	patients	_	_	_	_	_	_	_	_
18	for	_	_	_	_	_	_	_	_
19	their	_	_	_	_	_	_	_	_
20	risk	_	_	_	_	_	_	_	_
21	of	_	_	_	_	_	_	_	_
22	recurrence	_	_	_	_	_	_	_	_
23	.	_	_	_	_	_	_	_	_


1	The	_	_	_	_	_	_	_	_
2	present	_	_	_	_	_	_	_	_
3	findings	_	_	_	_	_	_	_	_
4	call	_	_	_	_	_	_	_	_
5	for	_	_	_	_	_	_	_	_
6	a	_	_	_	_	_	_	_	_
7	change	_	_	_	_	_	_	_	_
8	in	_	_	_	_	_	_	_	_
9	practice	_	_	_	_	_	_	_	_
10	,	_	_	_	_	_	_	_	_
11	aiming	_	_	_	_	_	_	_	_
12	for	_	_	_	_	_	_	_	_
13	a	_	_	_	_	_	_	_	_
14	faster	_	_	_	_	_	_	_	_
15	rise	_	_	_	_	_	_	_	_
16	in	_	_	_	_	_	_	_	_
17	mitotane	_	_	_	_	_	_	_	_
18	levels	_	_	_	_	_	_	_	_
19	and	_	_	_	_	_	_	_	_
20	strengthening	_	_	_	_	_	_	_	_
21	the	_	_	_	_	_	_	_	_
22	value	_	_	_	_	_	_	_	_
23	of	_	_	_	_	_	_	_	_
24	mitotane	_	_	_	_	_	_	_	_
25	monitoring	_	_	_	_	_	_	_	_
26	.	_	_	_	_	_	_	_	_


1	However	_	_	_	_	_	_	_	_
2	,	_	_	_	_	_	_	_	_
3	the	_	_	_	_	_	_	_	_
4	potential	_	_	_	_	_	_	_	_
5	danger	_	_	_	_	_	_	_	_
6	of	_	_	_	_	_	_	_	_
7	a	_	_	_	_	_	_	_	_
8	rapid	_	_	_	_	_	_	_	_
9	increment	_	_	_	_	_	_	_	_
10	in	_	_	_	_	_	_	_	_
11	mitotane	_	_	_	_	_	_	_	_
12	dosing	_	_	_	_	_	_	_	_
13	,	_	_	_	_	_	_	_	_
14	which	_	_	_	_	_	_	_	_
15	may	_	_	_	_	_	_	_	_
16	result	_	_	_	_	_	_	_	_
17	in	_	_	_	_	_	_	_	_
18	important	_	_	_	_	_	_	_	_
19	toxicity	_	_	_	_	_	_	_	_
20	with	_	_	_	_	_	_	_	_
21	consequent	_	_	_	_	_	_	_	_
22	loss	_	_	_	_	_	_	_	_
23	of	_	_	_	_	_	_	_	_
24	compliance	_	_	_	_	_	_	_	_
25	to	_	_	_	_	_	_	_	_
26	treatment	_	_	_	_	_	_	_	_
27	,	_	_	_	_	_	_	_	_
28	should	_	_	_	_	_	_	_	_
29	be	_	_	_	_	_	_	_	_
30	considered	_	_	_	_	_	_	_	_
31	.	_	_	_	_	_	_	_	_


1	We	_	_	_	_	_	_	_	_
2	found	_	_	_	_	_	_	_	_
3	only	_	_	_	_	_	_	_	_
4	a	_	_	_	_	_	_	_	_
5	weak	_	_	_	_	_	_	_	_
6	relationship	_	_	_	_	_	_	_	_
7	between	_	_	_	_	_	_	_	_
8	mitotane	_	_	_	_	_	_	_	_
9	dose	_	_	_	_	_	_	_	_
10	and	_	_	_	_	_	_	_	_
11	its	_	_	_	_	_	_	_	_
12	plasma	_	_	_	_	_	_	_	_
13	concentrations	_	_	_	_	_	_	_	_
14	during	_	_	_	_	_	_	_	_
15	the	_	_	_	_	_	_	_	_
16	first	_	_	_	_	_	_	_	_
17	phase	_	_	_	_	_	_	_	_
18	of	_	_	_	_	_	_	_	_
19	treatment	_	_	_	_	_	_	_	_
20	,	_	_	_	_	_	_	_	_
21	and	_	_	_	_	_	_	_	_
22	this	_	_	_	_	_	_	_	_
23	finding	_	_	_	_	_	_	_	_
24	is	_	_	_	_	_	_	_	_
25	in	_	_	_	_	_	_	_	_
26	agreement	_	_	_	_	_	_	_	_
27	with	_	_	_	_	_	_	_	_
28	the	_	_	_	_	_	_	_	_
29	concept	_	_	_	_	_	_	_	_
30	that	_	_	_	_	_	_	_	_
31	individual	_	_	_	_	_	_	_	_
32	differences	_	_	_	_	_	_	_	_
33	in	_	_	_	_	_	_	_	_
34	mitotane	_	_	_	_	_	_	_	_
35	metabolism	_	_	_	_	_	_	_	_
36	and	_	_	_	_	_	_	_	_
37	other	_	_	_	_	_	_	_	_
38	still	_	_	_	_	_	_	_	_
39	unknown	_	_	_	_	_	_	_	_
40	factors	_	_	_	_	_	_	_	_
41	influence	_	_	_	_	_	_	_	_
42	plasma	_	_	_	_	_	_	_	_
43	concentrations	_	_	_	_	_	_	_	_
44	.	_	_	_	_	_	_	_	_


1	Interestingly	_	_	_	_	_	_	_	_
2	,	_	_	_	_	_	_	_	_
3	higher	_	_	_	_	_	_	_	_
4	doses	_	_	_	_	_	_	_	_
5	were	_	_	_	_	_	_	_	_
6	employed	_	_	_	_	_	_	_	_
7	in	_	_	_	_	_	_	_	_
8	men	_	_	_	_	_	_	_	_
9	and	_	_	_	_	_	_	_	_
10	in	_	_	_	_	_	_	_	_
11	patients	_	_	_	_	_	_	_	_
12	with	_	_	_	_	_	_	_	_
13	greater	_	_	_	_	_	_	_	_
14	BMI	_	_	_	_	_	_	_	_
15	and	_	_	_	_	_	_	_	_
16	these	_	_	_	_	_	_	_	_
17	novel	_	_	_	_	_	_	_	_
18	findings	_	_	_	_	_	_	_	_
19	matter	_	_	_	_	_	_	_	_
20	for	_	_	_	_	_	_	_	_
21	clinical	_	_	_	_	_	_	_	_
22	practice	_	_	_	_	_	_	_	_
23	.	_	_	_	_	_	_	_	_


1	In	_	_	_	_	_	_	_	_
2	our	_	_	_	_	_	_	_	_
3	cohort	_	_	_	_	_	_	_	_
4	,	_	_	_	_	_	_	_	_
5	toxicity	_	_	_	_	_	_	_	_
6	associated	_	_	_	_	_	_	_	_
7	with	_	_	_	_	_	_	_	_
8	adjuvant	_	_	_	_	_	_	_	_
9	mitotane	_	_	_	_	_	_	_	_
10	was	_	_	_	_	_	_	_	_
11	acceptable	_	_	_	_	_	_	_	_
12	,	_	_	_	_	_	_	_	_
13	though	_	_	_	_	_	_	_	_
14	we	_	_	_	_	_	_	_	_
15	acknowledge	_	_	_	_	_	_	_	_
16	the	_	_	_	_	_	_	_	_
17	fact	_	_	_	_	_	_	_	_
18	that	_	_	_	_	_	_	_	_
19	due	_	_	_	_	_	_	_	_
20	to	_	_	_	_	_	_	_	_
21	the	_	_	_	_	_	_	_	_
22	study	_	_	_	_	_	_	_	_
23	inclusion	_	_	_	_	_	_	_	_
24	criteria	_	_	_	_	_	_	_	_
25	we	_	_	_	_	_	_	_	_
26	did	_	_	_	_	_	_	_	_
27	not	_	_	_	_	_	_	_	_
28	capture	_	_	_	_	_	_	_	_
29	the	_	_	_	_	_	_	_	_
30	patients	_	_	_	_	_	_	_	_
31	who	_	_	_	_	_	_	_	_
32	eventually	_	_	_	_	_	_	_	_
33	discontinued	_	_	_	_	_	_	_	_
34	mitotane	_	_	_	_	_	_	_	_
35	in	_	_	_	_	_	_	_	_
36	the	_	_	_	_	_	_	_	_
37	first	_	_	_	_	_	_	_	_
38	six	_	_	_	_	_	_	_	_
39	months	_	_	_	_	_	_	_	_
40	.	_	_	_	_	_	_	_	_


1	Severe	_	_	_	_	_	_	_	_
2	toxicity	_	_	_	_	_	_	_	_
3	leading	_	_	_	_	_	_	_	_
4	to	_	_	_	_	_	_	_	_
5	permanent	_	_	_	_	_	_	_	_
6	treatment	_	_	_	_	_	_	_	_
7	discontinuation	_	_	_	_	_	_	_	_
8	was	_	_	_	_	_	_	_	_
9	recorded	_	_	_	_	_	_	_	_
10	in	_	_	_	_	_	_	_	_
11	only	_	_	_	_	_	_	_	_
12	five	_	_	_	_	_	_	_	_
13	patients	_	_	_	_	_	_	_	_
14	on	_	_	_	_	_	_	_	_
15	chronic	_	_	_	_	_	_	_	_
16	therapy	_	_	_	_	_	_	_	_
17	,	_	_	_	_	_	_	_	_
18	and	_	_	_	_	_	_	_	_
19	this	_	_	_	_	_	_	_	_
20	is	_	_	_	_	_	_	_	_
21	likely	_	_	_	_	_	_	_	_
22	due	_	_	_	_	_	_	_	_
23	to	_	_	_	_	_	_	_	_
24	the	_	_	_	_	_	_	_	_
25	low	_	_	_	_	_	_	_	_
26	doses	_	_	_	_	_	_	_	_
27	(	_	_	_	_	_	_	_	_
28	median	_	_	_	_	_	_	_	_
29	dose	_	_	_	_	_	_	_	_
30	of	_	_	_	_	_	_	_	_
31	2	_	_	_	_	_	_	_	_
32	g/day	_	_	_	_	_	_	_	_
33	)	_	_	_	_	_	_	_	_
34	used	_	_	_	_	_	_	_	_
35	to	_	_	_	_	_	_	_	_
36	continue	_	_	_	_	_	_	_	_
37	treatment	_	_	_	_	_	_	_	_
38	in	_	_	_	_	_	_	_	_
39	the	_	_	_	_	_	_	_	_
40	maintenance	_	_	_	_	_	_	_	_
41	phase	_	_	_	_	_	_	_	_
42	.	_	_	_	_	_	_	_	_


1	Thus	_	_	_	_	_	_	_	_
2	,	_	_	_	_	_	_	_	_
3	the	_	_	_	_	_	_	_	_
4	present	_	_	_	_	_	_	_	_
5	study	_	_	_	_	_	_	_	_
6	shows	_	_	_	_	_	_	_	_
7	that	_	_	_	_	_	_	_	_
8	a	_	_	_	_	_	_	_	_
9	few	_	_	_	_	_	_	_	_
10	patients	_	_	_	_	_	_	_	_
11	cannot	_	_	_	_	_	_	_	_
12	tolerate	_	_	_	_	_	_	_	_
13	adjuvant	_	_	_	_	_	_	_	_
14	mitotane	_	_	_	_	_	_	_	_
15	following	_	_	_	_	_	_	_	_
16	the	_	_	_	_	_	_	_	_
17	first	_	_	_	_	_	_	_	_
18	months	_	_	_	_	_	_	_	_
19	of	_	_	_	_	_	_	_	_
20	treatment	_	_	_	_	_	_	_	_
21	,	_	_	_	_	_	_	_	_
22	proving	_	_	_	_	_	_	_	_
23	than	_	_	_	_	_	_	_	_
24	a	_	_	_	_	_	_	_	_
25	careful	_	_	_	_	_	_	_	_
26	follow-up	_	_	_	_	_	_	_	_
27	is	_	_	_	_	_	_	_	_
28	necessary	_	_	_	_	_	_	_	_
29	.	_	_	_	_	_	_	_	_


1	Despite	_	_	_	_	_	_	_	_
2	mitotane	_	_	_	_	_	_	_	_
3	having	_	_	_	_	_	_	_	_
4	a	_	_	_	_	_	_	_	_
5	reputation	_	_	_	_	_	_	_	_
6	for	_	_	_	_	_	_	_	_
7	being	_	_	_	_	_	_	_	_
8	a	_	_	_	_	_	_	_	_
9	challenging	_	_	_	_	_	_	_	_
10	drug	_	_	_	_	_	_	_	_
11	to	_	_	_	_	_	_	_	_
12	manage	_	_	_	_	_	_	_	_
13	,	_	_	_	_	_	_	_	_
14	adjuvant	_	_	_	_	_	_	_	_
15	mitotane	_	_	_	_	_	_	_	_
16	treatment	_	_	_	_	_	_	_	_
17	is	_	_	_	_	_	_	_	_
18	feasible	_	_	_	_	_	_	_	_
19	when	_	_	_	_	_	_	_	_
20	patients	_	_	_	_	_	_	_	_
21	are	_	_	_	_	_	_	_	_
22	managed	_	_	_	_	_	_	_	_
23	in	_	_	_	_	_	_	_	_
24	expert	_	_	_	_	_	_	_	_
25	centers	_	_	_	_	_	_	_	_
26	.	_	_	_	_	_	_	_	_


1	However	_	_	_	_	_	_	_	_
2	,	_	_	_	_	_	_	_	_
3	some	_	_	_	_	_	_	_	_
4	patients	_	_	_	_	_	_	_	_
5	were	_	_	_	_	_	_	_	_
6	unable	_	_	_	_	_	_	_	_
7	to	_	_	_	_	_	_	_	_
8	tolerate	_	_	_	_	_	_	_	_
9	the	_	_	_	_	_	_	_	_
10	drug	_	_	_	_	_	_	_	_
11	,	_	_	_	_	_	_	_	_
12	exhibiting	_	_	_	_	_	_	_	_
13	neurological	_	_	_	_	_	_	_	_
14	toxicity	_	_	_	_	_	_	_	_
15	even	_	_	_	_	_	_	_	_
16	when	_	_	_	_	_	_	_	_
17	exposed	_	_	_	_	_	_	_	_
18	to	_	_	_	_	_	_	_	_
19	“	_	_	_	_	_	_	_	_
20	normal	_	_	_	_	_	_	_	_
21	”	_	_	_	_	_	_	_	_
22	mitotane	_	_	_	_	_	_	_	_
23	concentrations	_	_	_	_	_	_	_	_
24	,	_	_	_	_	_	_	_	_
25	confirming	_	_	_	_	_	_	_	_
26	the	_	_	_	_	_	_	_	_
27	relevance	_	_	_	_	_	_	_	_
28	of	_	_	_	_	_	_	_	_
29	individual	_	_	_	_	_	_	_	_
30	factors	_	_	_	_	_	_	_	_
31	in	_	_	_	_	_	_	_	_
32	mitotane	_	_	_	_	_	_	_	_
33	metabolism	_	_	_	_	_	_	_	_
34	.	_	_	_	_	_	_	_	_


1	Strengths	_	_	_	_	_	_	_	_
2	of	_	_	_	_	_	_	_	_
3	the	_	_	_	_	_	_	_	_
4	present	_	_	_	_	_	_	_	_
5	study	_	_	_	_	_	_	_	_
6	are	_	_	_	_	_	_	_	_
7	the	_	_	_	_	_	_	_	_
8	thorough	_	_	_	_	_	_	_	_
9	characterization	_	_	_	_	_	_	_	_
10	of	_	_	_	_	_	_	_	_
11	adjuvant	_	_	_	_	_	_	_	_
12	mitotane	_	_	_	_	_	_	_	_
13	treatment	_	_	_	_	_	_	_	_
14	of	_	_	_	_	_	_	_	_
15	ACC	_	_	_	_	_	_	_	_
16	patients	_	_	_	_	_	_	_	_
17	following	_	_	_	_	_	_	_	_
18	surgical	_	_	_	_	_	_	_	_
19	removal	_	_	_	_	_	_	_	_
20	of	_	_	_	_	_	_	_	_
21	the	_	_	_	_	_	_	_	_
22	tumor	_	_	_	_	_	_	_	_
23	and	_	_	_	_	_	_	_	_
24	the	_	_	_	_	_	_	_	_
25	large	_	_	_	_	_	_	_	_
26	data	_	_	_	_	_	_	_	_
27	set	_	_	_	_	_	_	_	_
28	,	_	_	_	_	_	_	_	_
29	considering	_	_	_	_	_	_	_	_
30	the	_	_	_	_	_	_	_	_
31	rarity	_	_	_	_	_	_	_	_
32	of	_	_	_	_	_	_	_	_
33	the	_	_	_	_	_	_	_	_
34	disease	_	_	_	_	_	_	_	_
35	.	_	_	_	_	_	_	_	_


1	This	_	_	_	_	_	_	_	_
2	allowed	_	_	_	_	_	_	_	_
3	for	_	_	_	_	_	_	_	_
4	the	_	_	_	_	_	_	_	_
5	capture	_	_	_	_	_	_	_	_
6	of	_	_	_	_	_	_	_	_
7	details	_	_	_	_	_	_	_	_
8	of	_	_	_	_	_	_	_	_
9	mitotane	_	_	_	_	_	_	_	_
10	treatment	_	_	_	_	_	_	_	_
11	that	_	_	_	_	_	_	_	_
12	were	_	_	_	_	_	_	_	_
13	not	_	_	_	_	_	_	_	_
14	available	_	_	_	_	_	_	_	_
15	in	_	_	_	_	_	_	_	_
16	previous	_	_	_	_	_	_	_	_
17	studies	_	_	_	_	_	_	_	_
18	and	_	_	_	_	_	_	_	_
19	led	_	_	_	_	_	_	_	_
20	to	_	_	_	_	_	_	_	_
21	observations	_	_	_	_	_	_	_	_
22	that	_	_	_	_	_	_	_	_
23	may	_	_	_	_	_	_	_	_
24	be	_	_	_	_	_	_	_	_
25	useful	_	_	_	_	_	_	_	_
26	to	_	_	_	_	_	_	_	_
27	informing	_	_	_	_	_	_	_	_
28	future	_	_	_	_	_	_	_	_
29	practice	_	_	_	_	_	_	_	_
30	.	_	_	_	_	_	_	_	_


1	However	_	_	_	_	_	_	_	_
2	,	_	_	_	_	_	_	_	_
3	we	_	_	_	_	_	_	_	_
4	should	_	_	_	_	_	_	_	_
5	acknowledge	_	_	_	_	_	_	_	_
6	the	_	_	_	_	_	_	_	_
7	limits	_	_	_	_	_	_	_	_
8	of	_	_	_	_	_	_	_	_
9	a	_	_	_	_	_	_	_	_
10	retrospective	_	_	_	_	_	_	_	_
11	analysis	_	_	_	_	_	_	_	_
12	,	_	_	_	_	_	_	_	_
13	and	_	_	_	_	_	_	_	_
14	that	_	_	_	_	_	_	_	_
15	our	_	_	_	_	_	_	_	_
16	results	_	_	_	_	_	_	_	_
17	are	_	_	_	_	_	_	_	_
18	not	_	_	_	_	_	_	_	_
19	generalizable	_	_	_	_	_	_	_	_
20	to	_	_	_	_	_	_	_	_
21	patients	_	_	_	_	_	_	_	_
22	who	_	_	_	_	_	_	_	_
23	discontinue	_	_	_	_	_	_	_	_
24	treatment	_	_	_	_	_	_	_	_
25	within	_	_	_	_	_	_	_	_
26	six	_	_	_	_	_	_	_	_
27	months	_	_	_	_	_	_	_	_
28	for	_	_	_	_	_	_	_	_
29	intolerability	_	_	_	_	_	_	_	_
30	or	_	_	_	_	_	_	_	_
31	patients	_	_	_	_	_	_	_	_
32	with	_	_	_	_	_	_	_	_
33	early	_	_	_	_	_	_	_	_
34	ACC	_	_	_	_	_	_	_	_
35	recurrence	_	_	_	_	_	_	_	_
36	.	_	_	_	_	_	_	_	_


1	The	_	_	_	_	_	_	_	_
2	inclusion	_	_	_	_	_	_	_	_
3	criteria	_	_	_	_	_	_	_	_
4	of	_	_	_	_	_	_	_	_
5	the	_	_	_	_	_	_	_	_
6	study	_	_	_	_	_	_	_	_
7	produced	_	_	_	_	_	_	_	_
8	an	_	_	_	_	_	_	_	_
9	immortal	_	_	_	_	_	_	_	_
10	time	_	_	_	_	_	_	_	_
11	of	_	_	_	_	_	_	_	_
12	six	_	_	_	_	_	_	_	_
13	months	_	_	_	_	_	_	_	_
14	that	_	_	_	_	_	_	_	_
15	may	_	_	_	_	_	_	_	_
16	have	_	_	_	_	_	_	_	_
17	enriched	_	_	_	_	_	_	_	_
18	our	_	_	_	_	_	_	_	_
19	series	_	_	_	_	_	_	_	_
20	of	_	_	_	_	_	_	_	_
21	a	_	_	_	_	_	_	_	_
22	higher	_	_	_	_	_	_	_	_
23	number	_	_	_	_	_	_	_	_
24	of	_	_	_	_	_	_	_	_
25	low-risk	_	_	_	_	_	_	_	_
26	ACC	_	_	_	_	_	_	_	_
27	compared	_	_	_	_	_	_	_	_
28	to	_	_	_	_	_	_	_	_
29	recently	_	_	_	_	_	_	_	_
30	published	_	_	_	_	_	_	_	_
31	series	_	_	_	_	_	_	_	_
32	.	_	_	_	_	_	_	_	_

